MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
90.60
-0.50 (-0.55%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close91.10
Open91.29
Bid90.70 x 800
Ask90.99 x 2200
Day's Range90.42 - 91.34
52 Week Range76.41 - 91.50
Volume8,973,185
Avg. Volume4,452,992
Market Cap122.465B
Beta0.75
PE Ratio (TTM)39.91
EPS (TTM)2.27
Earnings DateAug 21, 2018
Forward Dividend & Yield2.00 (2.26%)
Ex-Dividend Date2018-07-05
1y Target Est95.55
Trade prices are not sourced from all markets
  • Appeals court deals Medtronic blow in $1.4B dispute with IRS
    American City Business Journalsyesterday

    Appeals court deals Medtronic blow in $1.4B dispute with IRS

    The ruling relates to a complex and years-long battle over how Medtronic accounted for business at its Puerto Rico manufacturing facilities.

  • CNBC2 days ago

    Security researchers say they can hack Medtronic pacemakers

    Security researchers say they've found flaws in the Medtronic pacemaker that leaves the life-saving device vulnerable to hackers and puts patients at risk. The two researchers demonstrated the security weaknesses earlier this month at the annual Black Hat cyber security conference in Las Vegas. Security researchers say they've found flaws in the Medtronic MDT pacemaker that leaves the life-saving device vulnerable to hackers and puts patients at risk.

  • Medtronic plc’s (NYSE:MDT) Insiders Just Sold Shares – Should You?
    Simply Wall St.2 days ago

    Medtronic plc’s (NYSE:MDT) Insiders Just Sold Shares – Should You?

    Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. Medtronic’s insiders have divested from 20.41k shares in the large-cap stock within theRead More...

  • Will Medtronic (MDT) Q1 Earnings Show Overall Progress?
    Zacks2 days ago

    Will Medtronic (MDT) Q1 Earnings Show Overall Progress?

    In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.

  • Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
    Zacks3 days ago

    Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

    Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

  • Treatment with ITB Therapy vs. Oral Medication Shows Quality of Life Improvement, Reduction in Spasticity-Related Pain
    GlobeNewswire3 days ago

    Treatment with ITB Therapy vs. Oral Medication Shows Quality of Life Improvement, Reduction in Spasticity-Related Pain

    Therapy Delivered via the Medtronic SynchroMed TM II Infusion System DUBLIN - August 16, 2018 - Medtronic plc (NYSE:MDT) today announced the online publication of `Effect of intrathecal baclofen on pain ...

  • Medtronic Announces Commercial Launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon in Japan
    GlobeNewswire4 days ago

    Medtronic Announces Commercial Launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon in Japan

    August 15, 2018 - Medtronic plc (MDT) today announced full commercial launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) in Japan. IN.PACT Admiral received approval last year from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg - specifically, in the thigh (superficial femoral arteries (SFA)) and behind the knee (popliteal arteries). "In Japan, there is a significant need for new technologies to safely and effectively treat PAD," said Tony Semedo, president, Medtronic Japan.

  • GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
    Market Realist5 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.

  • Becton, Dickinson Global Foothold Strong, Recalls Rampant
    Zacks6 days ago

    Becton, Dickinson Global Foothold Strong, Recalls Rampant

    Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

  • What Does Tandem Diabetes Care’s Valuation Trend Indicate?
    Market Realist10 days ago

    What Does Tandem Diabetes Care’s Valuation Trend Indicate?

    From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.

  • Gauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions
    Market Realist10 days ago

    Gauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions

    Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.

  • Dentsply Sirona’s Segments: Q2 2018 Performance
    Market Realist10 days ago

    Dentsply Sirona’s Segments: Q2 2018 Performance

    Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.

  • See what the IHS Markit Score report has to say about Medtronic PLC.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Medtronic PLC.

    Medtronic PLC NYSE:MDT

  • CNBC11 days ago

    Alphabet, Apple and two other stocks to buy as the S&P nears records

    After more than six months since its last high, the S&P 500 is back on the road to records. "We think the S&P is going to breakthrough that January resistance. You want to own stocks," Ari Wald, head of technical analysis at Oppenheimer, told CNBC's " Trading Nation " on Tuesday.

  • Bloomberg11 days ago

    The $250 Biohack That’s Revolutionizing Life With Diabetes

    When her daughter, Sydney, was diagnosed with Type 1 diabetes at age 8, Kate Farnsworth stopped sleeping through the night. At 6 a.m., another alarm went off to signal the next insulin dose, but by then, Kate had usually snapped awake again already. When Sydney got home from school each afternoon, Kate was there to check her glucose level.

  • InvestorPlace13 days ago

    Mazor Robotics Is Still Expensive Despite Recent Drop

    Mazor Robotics (NASDAQ:MZOR) fell nearly 15 percent last week after the company reported second-quarter results. Mazor Robotics reported revenue of $13.2 million as customers adopted its technologies in robotic guidance systems. At 20 times sales, MZOR stock is not cheap.

  • What Analysts Recommend for Haemonetics
    Market Realist13 days ago

    What Analysts Recommend for Haemonetics

    Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.

  • What Analysts Expect from Haemonetics in Q1 2019
    Market Realist13 days ago

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.

  • InvestorPlace13 days ago

    IntriCon Is the Best A-Rated Stock You’ve Never Heard Of

    IntriCon Corporation (NASDAQ:IIN) is a small company with big promise. Granted, its market cap is less than $500 million, so now that investors see the growth potential, the stock is getting a lot of attention from mutual funds, institutional investors and momentum traders.

  • Mazor Robotics' Q2 Revenue Declines Despite Volume Gains
    Motley Fool15 days ago

    Mazor Robotics' Q2 Revenue Declines Despite Volume Gains

    System placements grew 25%, but lower pricing terms from its commercial deal with Medtronic cause the top line to head in reverse.

  • Investopedia16 days ago

    Medical Device Stocks on the Move

    On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.

  • What Analysts Recommend for Boston Scientific, Post-Q2 Results
    Market Realist16 days ago

    What Analysts Recommend for Boston Scientific, Post-Q2 Results

    Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.

  • United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
    Zacks17 days ago

    United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

    United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

  • Why Mazor Robotics Is Tanking Today
    Motley Fool17 days ago

    Why Mazor Robotics Is Tanking Today

    Shares tumble after second-quarter results miss the mark. Here's what you need to know.

  • Medtronic pacemakers may be at risk from hackers
    CNBC Videos2 days ago

    Medtronic pacemakers may be at risk from hackers

    Security researchers have discovered multiple security flaws that could allow a malicious hacker to tamper with a Medtronic pacemaker.